Advertisement

Drugs

, Volume 74, Issue 10, pp 1147–1152 | Cite as

Siltuximab: First Global Approval

  • Anthony Markham
  • Trina PatelEmail author
R&D Insight Report

Abstract

The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman’s disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and from an accelerated assessment and recommendation by the Committee for Medicinal Products for Human Use (CHMP) in the EU. Development of the drug is continuing in smoldering multiple myeloma. This article summarizes the milestones in the development of siltuximab leading to this first approval for MCD.

Keywords

European Union Multiple Myeloma Bortezomib Tocilizumab CHMP 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this report was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM. T. Patel is a salaried employee of Adis, Springer SBM.

References

  1. 1.
    Van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8(7):486–98.PubMedGoogle Scholar
  2. 2.
    El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497–511.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Fajgenbaum D, van Rhee F, Nabel C. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014. doi: 10.1182/blood-2013-12-545087.PubMedGoogle Scholar
  4. 4.
    Chugai Pharmaceutical. Chugai Pharmaceutical’s innovative Castleman’s disease drug ACTEMRA now available in Japan (media release), 14 June 2005. www.japancorp.net.
  5. 5.
    US Food and Drug Administration. FDA approves Sylvant for rare Castleman’s disease (media release), 23 April 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394522.htm.
  6. 6.
    Janssen Biotech. SYLVANT(Tm) (siltuximab) Receives FDA Approval to treat multicentric Castleman’s disease (MCD): first treatment approved for patients with rare blood disorder (media release), 23 April 2014. http://www.janssenbiotech.com.
  7. 7.
    US Food and Drug Administration. SYLVANT prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf. Accessed 15 May 2014.
  8. 8.
    European Commission. Community register of medicinal products for human use: SYLANT authorisation 2014. http://ec.europa.eu/health/documents/community-register/html/h928.htm. Accessed 10 Jun 2014.
  9. 9.
    Committee for Medicinal Products for Human Use (CHMP) EMA. Summary of opinion (initial authorisation) Sylvant Siltuximab. 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/03/WC500163529.pdf.
  10. 10.
    Guo Y, Nemeth J, O’Brien C, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010;16(23):5759–69.PubMedCrossRefGoogle Scholar
  11. 11.
    Cavarretta IT, Neuwirt H, Zaki MH, et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008;617:547–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Hunsucker SA, Magarotto V, Kuhn DJ, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011;152(5):579–92.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009;145(4):481–90.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Karkera J, Steiner H, Li W, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011;71(13):1455–65.PubMedCrossRefGoogle Scholar
  15. 15.
    van Zaanen HC, Koopmans RP, Aarden LA, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest. 1996;98(6):1441–8.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Coward J, Kulbe H, Leader D, et al. Interleukin-6 as a therapeutic target in advanced ovarian cancer [abstract no. 5331]. In: 101st Annual Meeting of the American Association for Cancer Research; 17-21 Apr 2010; Washington, DC.Google Scholar
  17. 17.
    Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653–65.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Puchalski T, Prabhakar U, Jiao Q, et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010;16(5):1652–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Xie L, Li LY, Kurzrock R, et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-Hodgkin’s lymphoma, multiple myeloma, or Castleman’s disease. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).Google Scholar
  20. 20.
    Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19(13):3659–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Angevin E, Elez E, Cohen SJ, et al. Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors [abstract no. 2583]. J Clin Oncol Conf. 2012;30(15 suppl).Google Scholar
  22. 22.
    Wong RS, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
  23. 23.
    Van Rhee F, Casper C, Voorhees PM, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
  24. 24.
    Kirk M, Kurzrock R, Van Rhee F, et al. Siltuximab reverses muscle wasting in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
  25. 25.
    San Miguel J, Blade J, Shpilberg O, et al. Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. 2014. doi: 10.1182/blood-2013-12-546374.
  26. 26.
    Orlowski RZ, Gercheva L, Williams C, et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/ refractory multiple myeloma [abstract no. 8018]. J Clin Oncol 2012;30(Suppl).Google Scholar
  27. 27.
    Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161(3):357–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand
  2. 2.AdisAucklandNew Zealand

Personalised recommendations